JP2014158480A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014158480A5 JP2014158480A5 JP2014070238A JP2014070238A JP2014158480A5 JP 2014158480 A5 JP2014158480 A5 JP 2014158480A5 JP 2014070238 A JP2014070238 A JP 2014070238A JP 2014070238 A JP2014070238 A JP 2014070238A JP 2014158480 A5 JP2014158480 A5 JP 2014158480A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- variable region
- chain variable
- heavy chain
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108090000623 proteins and genes Proteins 0.000 claims 30
- 102000004169 proteins and genes Human genes 0.000 claims 30
- 101100437153 Rattus norvegicus Acvr2b gene Proteins 0.000 claims 11
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 201000011510 cancer Diseases 0.000 claims 9
- 208000023178 Musculoskeletal disease Diseases 0.000 claims 8
- 102000004472 Myostatin Human genes 0.000 claims 8
- 108010056852 Myostatin Proteins 0.000 claims 8
- 239000000556 agonist Substances 0.000 claims 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 150000001413 amino acids Chemical class 0.000 claims 8
- 208000019425 cirrhosis of liver Diseases 0.000 claims 8
- 102000040430 polynucleotide Human genes 0.000 claims 7
- 108091033319 polynucleotide Proteins 0.000 claims 7
- 239000002157 polynucleotide Substances 0.000 claims 7
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims 6
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims 6
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 claims 6
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 claims 6
- 208000021642 Muscular disease Diseases 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 230000002779 inactivation Effects 0.000 claims 5
- 238000000034 method Methods 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 208000030090 Acute Disease Diseases 0.000 claims 3
- 206010065687 Bone loss Diseases 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 102000016970 Follistatin Human genes 0.000 claims 3
- 108010014612 Follistatin Proteins 0.000 claims 3
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 3
- 206010019629 Hepatic adenoma Diseases 0.000 claims 3
- 101000685982 Homo sapiens NAD(+) hydrolase SARM1 Proteins 0.000 claims 3
- 208000002404 Liver Cell Adenoma Diseases 0.000 claims 3
- 102100023356 NAD(+) hydrolase SARM1 Human genes 0.000 claims 3
- 208000018737 Parkinson disease Diseases 0.000 claims 3
- 230000001154 acute effect Effects 0.000 claims 3
- 208000020832 chronic kidney disease Diseases 0.000 claims 3
- 230000007882 cirrhosis Effects 0.000 claims 3
- 210000003414 extremity Anatomy 0.000 claims 3
- 201000002735 hepatocellular adenoma Diseases 0.000 claims 3
- 208000017445 musculoskeletal system disease Diseases 0.000 claims 3
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 3
- 239000000849 selective androgen receptor modulator Substances 0.000 claims 3
- 208000024806 Brain atrophy Diseases 0.000 claims 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 101800001586 Ghrelin Proteins 0.000 claims 2
- 102400000442 Ghrelin-28 Human genes 0.000 claims 2
- 206010023421 Kidney fibrosis Diseases 0.000 claims 2
- 201000002481 Myositis Diseases 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 208000007502 anemia Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000016273 neuron death Effects 0.000 claims 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 2
- 239000013598 vector Substances 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 206010010356 Congenital anomaly Diseases 0.000 claims 1
- 206010013883 Dwarfism Diseases 0.000 claims 1
- 238000002965 ELISA Methods 0.000 claims 1
- 229920002527 Glycogen Polymers 0.000 claims 1
- 102100022745 Laminin subunit alpha-2 Human genes 0.000 claims 1
- 208000010557 Lipid storage disease Diseases 0.000 claims 1
- 206010068836 Metabolic myopathy Diseases 0.000 claims 1
- 206010028289 Muscle atrophy Diseases 0.000 claims 1
- 206010049565 Muscle fatigue Diseases 0.000 claims 1
- 206010028629 Myoglobinuria Diseases 0.000 claims 1
- 201000009623 Myopathy Diseases 0.000 claims 1
- 206010061533 Myotonia Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 208000020221 Short stature Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 229940124748 beta 2 agonist Drugs 0.000 claims 1
- 238000010367 cloning Methods 0.000 claims 1
- 239000013599 cloning vector Substances 0.000 claims 1
- 201000006815 congenital muscular dystrophy Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 230000001815 facial effect Effects 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 claims 1
- 229940096919 glycogen Drugs 0.000 claims 1
- 208000007345 glycogen storage disease Diseases 0.000 claims 1
- 238000011540 hip replacement Methods 0.000 claims 1
- 201000008319 inclusion body myositis Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 210000003127 knee Anatomy 0.000 claims 1
- 238000013150 knee replacement Methods 0.000 claims 1
- 210000002414 leg Anatomy 0.000 claims 1
- 108020001756 ligand binding domains Proteins 0.000 claims 1
- 208000014416 lysosomal lipid storage disease Diseases 0.000 claims 1
- 210000003470 mitochondria Anatomy 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 230000020763 muscle atrophy Effects 0.000 claims 1
- 201000000585 muscular atrophy Diseases 0.000 claims 1
- 230000005996 muscular dysfunction Effects 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 230000000737 periodic effect Effects 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 230000002035 prolonged effect Effects 0.000 claims 1
- 238000003571 reporter gene assay Methods 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 230000002269 spontaneous effect Effects 0.000 claims 1
- 210000003699 striated muscle Anatomy 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 210000005239 tubule Anatomy 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17300409P | 2009-04-27 | 2009-04-27 | |
| US61/173,004 | 2009-04-27 | ||
| US30613710P | 2010-02-19 | 2010-02-19 | |
| US61/306,137 | 2010-02-19 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012507695A Division JP5766179B2 (ja) | 2009-04-27 | 2010-04-23 | 筋肉増殖を増加させるための組成物および方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016129498A Division JP2017014207A (ja) | 2009-04-27 | 2016-06-30 | 筋肉増殖を増加させるための組成物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014158480A JP2014158480A (ja) | 2014-09-04 |
| JP2014158480A5 true JP2014158480A5 (enExample) | 2015-04-23 |
Family
ID=42306628
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012507695A Active JP5766179B2 (ja) | 2009-04-27 | 2010-04-23 | 筋肉増殖を増加させるための組成物および方法 |
| JP2014070238A Withdrawn JP2014158480A (ja) | 2009-04-27 | 2014-03-28 | 筋肉増殖を増加させるための組成物および方法 |
| JP2016129498A Pending JP2017014207A (ja) | 2009-04-27 | 2016-06-30 | 筋肉増殖を増加させるための組成物および方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012507695A Active JP5766179B2 (ja) | 2009-04-27 | 2010-04-23 | 筋肉増殖を増加させるための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016129498A Pending JP2017014207A (ja) | 2009-04-27 | 2016-06-30 | 筋肉増殖を増加させるための組成物および方法 |
Country Status (41)
Families Citing this family (102)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3059245B1 (en) * | 2004-07-23 | 2018-11-07 | Acceleron Pharma Inc. | Actrii receptor antagonistic antibodies |
| ES2852549T3 (es) | 2005-02-09 | 2021-09-13 | Sarepta Therapeutics Inc | Composición antisentido para tratamiento de la atrofia muscular |
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| MX2008006626A (es) | 2005-11-23 | 2008-09-24 | Acceleron Pharma Inc | Antagonistas de activin-actriia y usos para promover el crecimiento de huesos. |
| US20100028332A1 (en) * | 2006-12-18 | 2010-02-04 | Acceleron Pharma Inc. | Antagonists of actriib and uses for increasing red blood cell levels |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| WO2008094708A2 (en) | 2007-02-01 | 2008-08-07 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for treating or preventing breast cancer |
| TWI782836B (zh) * | 2007-02-02 | 2022-11-01 | 美商艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
| TWI606062B (zh) | 2007-02-09 | 2017-11-21 | 艾瑟勒朗法瑪公司 | 包含ＡｃｔＲＩＩａ-Ｆｃ融合蛋白的醫藥組合物；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防與癌症相關的骨質流失之用途；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防多發性骨髓瘤之用途 |
| TWI573802B (zh) | 2007-03-06 | 2017-03-11 | 安美基公司 | 變異之活動素受體多肽及其用途 |
| WO2009038745A1 (en) | 2007-09-18 | 2009-03-26 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion |
| CA2729096C (en) * | 2008-06-26 | 2020-04-28 | Acceleron Pharma Inc. | Methods for dosing an actriib antagonist and monitoring of treated patients |
| HRP20191109T1 (hr) | 2008-08-14 | 2019-09-20 | Acceleron Pharma Inc. | Gdf klopke za uporabu u liječenju anemije |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| LT2370463T (lt) | 2008-11-26 | 2016-12-12 | Amgen Inc. | Stabilizuotas aktivino iib receptoriaus variantas |
| WO2010083034A1 (en) * | 2009-01-13 | 2010-07-22 | Acceleron Pharma Inc. | Methods for increasing adiponectin |
| SG174273A1 (en) * | 2009-04-27 | 2011-10-28 | Novartis Ag | Compositions and methods for increasing muscle growth |
| AU2010258931B2 (en) * | 2009-06-08 | 2015-04-23 | Acceleron Pharma Inc. | Methods for increasing thermogenic adipocytes |
| CN107267520A (zh) | 2009-06-12 | 2017-10-20 | 阿塞勒隆制药公司 | 截短的actriib‑fc融合蛋白 |
| ES2869580T3 (es) * | 2009-09-09 | 2021-10-25 | Acceleron Pharma Inc | Antagonistas de ActRIIB y dosificación y usos de los mismos para tratar obesidad o diabetes tipo 2 regulando el contenido de grasa corporal |
| EP3260130B1 (en) * | 2009-11-03 | 2021-03-10 | Acceleron Pharma Inc. | Methods for treating fatty liver disease |
| CA2781152A1 (en) | 2009-11-17 | 2011-05-26 | Acceleron Pharma Inc. | Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
| JO3340B1 (ar) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
| US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| RS63430B1 (sr) | 2010-10-01 | 2022-08-31 | Modernatx Inc | Ribonukleinske kiseline koje sadrže n1-metil-pseudouracile i njihove primene |
| JP2014502260A (ja) | 2010-11-08 | 2014-01-30 | アクセルロン ファーマ， インコーポレイテッド | Ａｃｔｒｉｉａ結合剤およびその使用 |
| EP2691101A2 (en) | 2011-03-31 | 2014-02-05 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| WO2013006437A1 (en) | 2011-07-01 | 2013-01-10 | Novartis Ag | Method for treating metabolic disorders |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| DK3682905T3 (da) | 2011-10-03 | 2022-02-28 | Modernatx Inc | Modificerede nukleosider, nukleotider og nukleinsyrer og anvendelser deraf |
| US20130085139A1 (en) | 2011-10-04 | 2013-04-04 | Royal Holloway And Bedford New College | Oligomers |
| US8765385B2 (en) | 2011-10-27 | 2014-07-01 | Ravindra Kumar | Method of detection of neutralizing anti-actriib antibodies |
| WO2013063536A1 (en) * | 2011-10-27 | 2013-05-02 | Acceleron Pharma, Inc. | Actriib binding agents and uses thereof |
| WO2013074557A1 (en) | 2011-11-14 | 2013-05-23 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and/or activin a |
| DE12858350T1 (de) | 2011-12-16 | 2021-10-07 | Modernatx, Inc. | Modifizierte mrna zusammensetzungen |
| US10039813B2 (en) | 2012-02-07 | 2018-08-07 | Massachusetts Institute Of Technology | Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| HK1206601A1 (en) | 2012-04-02 | 2016-01-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of biologics and proteins associated with human disease |
| US9453080B2 (en) * | 2012-06-11 | 2016-09-27 | Amgen Inc. | Dual receptor antagonistic antigen-binding proteins and uses thereof |
| JP6214537B2 (ja) * | 2012-08-21 | 2017-10-25 | 国立大学法人九州大学 | 貧血患者の貧血の要因を検出するためのバイオマーカー |
| IL290653B2 (en) * | 2012-10-24 | 2025-05-01 | Celgene Corp | Biomarker for use in the treatment of anemia |
| ES2884095T3 (es) | 2012-11-02 | 2021-12-10 | Celgene Corp | Antagonistas de activina-actrii y usos para el tratamiento de trastornos óseos y otros trastornos |
| HRP20220607T1 (hr) | 2012-11-26 | 2022-06-24 | Modernatx, Inc. | Terminalno modificirana rna |
| BR112015013708B1 (pt) | 2012-12-18 | 2022-10-18 | Novartis Ag | Polipeptídeo compreendendo uma proteína igf-1 humana, seu uso, polinucleotídeo e composição farmacêutica |
| EP3985024A1 (en) | 2013-02-01 | 2022-04-20 | Atara Biotherapeutics, Inc. | Anti-activin-a compounds for the treatment of ovarian cancer |
| US9724396B2 (en) | 2013-03-15 | 2017-08-08 | Massachusetts Institute Of Technology | Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| WO2014172448A2 (en) * | 2013-04-17 | 2014-10-23 | Anaptysbio, Inc. | Antibodies directed against activin receptor type ii (actrii) |
| TWI655207B (zh) | 2013-07-30 | 2019-04-01 | 再生元醫藥公司 | 抗活化素ａ之抗體及其用途 |
| US20160200818A1 (en) * | 2013-08-14 | 2016-07-14 | Novartis Ag | Methods of treating Sporadic Inclusion Body Myositis |
| EP3756661A1 (en) | 2013-09-09 | 2020-12-30 | vTv Therapeutics LLC | Use of a ppar-delta agonist for treating muscle atrophy |
| WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
| EP3052123A1 (en) | 2013-10-02 | 2016-08-10 | Novartis Ag | Insulin-like growth factor mimetics for use in therapy |
| WO2015051214A1 (en) | 2013-10-03 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| UY35874A (es) | 2013-12-12 | 2015-07-31 | Novartis Ag | Un proceso para la preparación de una composición de proteínas pegiladas |
| EP3094751A4 (en) * | 2014-01-14 | 2017-06-07 | Santa Maria Biotherapeutics, Inc. | Activin inhibitor response prediction and uses for treatment |
| CN105992951A (zh) | 2014-01-27 | 2016-10-05 | 诺华股份有限公司 | 预测肌萎缩的生物标志物、方法和用途 |
| TW201622746A (zh) * | 2014-04-24 | 2016-07-01 | 諾華公司 | 改善或加速髖部骨折術後身體復原之方法 |
| MA40008A (fr) | 2014-06-13 | 2021-05-05 | Acceleron Pharma Inc | Antagoniste actrii pour le traitement et la prevention d'un ulcere cutane chez un sujet ayant l'anemie |
| MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| EP3215175A4 (en) | 2014-11-06 | 2018-06-27 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
| WO2016090035A2 (en) * | 2014-12-02 | 2016-06-09 | La Jolla Institute For Allergy And Immunology | Modulators of activin and methods for modulating immune responses and t follicular helper cells |
| AU2015358469B2 (en) | 2014-12-03 | 2021-05-27 | Acceleron Pharma Inc. | Activin-ActRII antagonists and uses for treating anemia |
| US20170260275A1 (en) | 2014-12-08 | 2017-09-14 | Novartis Ag | Myostatin or activin antagonists for the treatment of sarcopenia |
| US10317418B2 (en) | 2015-02-24 | 2019-06-11 | Massachusetts Institute Of Technology | Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness |
| MA41795A (fr) | 2015-03-18 | 2018-01-23 | Sarepta Therapeutics Inc | Exclusion d'un exon induite par des composés antisens dans la myostatine |
| EP3283519A1 (en) | 2015-04-15 | 2018-02-21 | Regeneron Pharmaceuticals, Inc. | Methods of increasing strength and functionality with gdf8 inhibitors |
| SG10201913747PA (en) | 2015-04-22 | 2020-03-30 | Biogen Ma Inc | Novel hybrid actriib ligand trap proteins for treating muscle wasting diseases |
| PL3350220T3 (pl) | 2015-09-15 | 2022-01-03 | Scholar Rock, Inc. | Przeciwciała przeciwko pro/latentnej miostatynie i ich zastosowania |
| WO2017062835A2 (en) | 2015-10-09 | 2017-04-13 | Sarepta Therapeutics, Inc. | Compositions and methods for treating duchenne muscular dystrophy and related disorders |
| HK1254630A1 (zh) | 2015-11-11 | 2019-07-26 | Novartis Ag | 肌抑素拮抗剂的用途、含有它们的组合及其用途 |
| AU2017206069A1 (en) | 2016-01-08 | 2018-07-19 | Scholar Rock, Inc. | Anti-pro/latent myostatin antibodies and methods of use thereof |
| US11180546B2 (en) | 2016-02-17 | 2021-11-23 | Novartis Ag | TGFbeta 2 antibodies |
| PL3426680T3 (pl) * | 2016-03-10 | 2025-03-31 | Acceleron Pharma Inc. | Białka wiążące receptor aktywiny typu 2 i ich zastosowania |
| US20170306027A1 (en) | 2016-04-06 | 2017-10-26 | Acceleron Pharma Inc. | Alk7 antagonists and uses thereof |
| US11312766B2 (en) * | 2016-04-27 | 2022-04-26 | Novartis Ag | Antibodies against growth differentiation factor 15 and uses thereof |
| PT3368069T (pt) * | 2016-06-13 | 2020-11-11 | Scholar Rock Inc | Uso de inibidores da miostatina e terapias de combinação |
| US20200306244A1 (en) | 2016-06-22 | 2020-10-01 | Novartis Ag | Wnt inhibitors for use in the treatment of fibrosis |
| EP3522934A4 (en) * | 2016-10-05 | 2020-04-15 | Acceleron Pharma Inc. | COMPOSITIONS AND METHODS FOR TREATING KIDNEY DISEASES |
| JOP20190085A1 (ar) | 2016-10-20 | 2019-04-17 | Biogen Ma Inc | طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة |
| GB201620119D0 (en) * | 2016-11-29 | 2017-01-11 | Pharmafox Therapeutics Ag | Compounds |
| JOP20190152A1 (ar) | 2016-12-21 | 2019-06-20 | Novartis Ag | مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة |
| SI3565592T1 (sl) | 2017-01-06 | 2023-05-31 | Scholar Rock, Inc. | Zdravljenje presnovnih bolezni z zaviranjem aktivacije miostatina |
| US11693013B2 (en) | 2017-03-10 | 2023-07-04 | UCL Business Ltd. | Method relating to myostatin pathway inhibition |
| IL269083B2 (en) | 2017-03-24 | 2024-12-01 | Novartis Ag | Methods for preventing and treating heart disease |
| TW201906865A (zh) * | 2017-06-28 | 2019-02-16 | 瑞士商諾華公司 | 預防及治療尿失禁之方法 |
| IL321873A (en) | 2018-03-01 | 2025-08-01 | Regeneron Pharma | Methods for altering body composition |
| JP7669291B2 (ja) * | 2019-05-30 | 2025-04-28 | アクセレロン ファーマ インコーポレーテッド | Ａｃｔｒｉｉ結合性タンパク質及びその使用 |
| JP7663559B2 (ja) * | 2019-09-03 | 2025-04-16 | ノバルティス アーゲー | Ａｃｔｒｉｉ受容体拮抗薬を含む肝疾患または肝臓障害の治療 |
| EP4200017A1 (en) | 2020-08-20 | 2023-06-28 | Regeneron Pharmaceuticals, Inc. | Methods for preventing and treating cardiac dysfunction and covid-19 with activin a antagonists |
| EP4279594A4 (en) * | 2021-01-13 | 2024-11-27 | Astellas Pharma Inc. | BINDING OF MULTISPECIFIC ANTIBODIES TO ACTRIIA, ACTRIIB AND FN14 |
| MX2024002467A (es) | 2021-08-27 | 2024-05-20 | Versanis Bio Inc | Terapias combinadas. |
| WO2023147309A1 (en) | 2022-01-25 | 2023-08-03 | Reneo Pharmaceuticals, Inc. | Use of ppar-delta agonists in the treatment of disease |
| WO2024014989A1 (ru) * | 2022-07-14 | 2024-01-18 | Общество с ограниченной ответственностью "БИОМЕД-РЕСУРС" | Рекомбинантный белок gbd-actriib для увеличения мышечной массы сельскохозяйственных животных и птицы |
| WO2024044782A1 (en) | 2022-08-26 | 2024-02-29 | Versanis Bio, Inc. | Actrii antibody fixed unit dose treatments |
| KR20250122524A (ko) | 2022-12-22 | 2025-08-13 | 스칼러 락, 인크. | 미오스타틴 활성화의 선택적이고 강력한 억제 항체 |
| WO2025027052A1 (en) | 2023-07-31 | 2025-02-06 | Sixpeaks Bio Ag | Antibody conjugates and fusion proteins |
| TW202521582A (zh) | 2023-09-28 | 2025-06-01 | 瑞士商六峰生物股份有限公司 | 靶向ActRIIA及ActRIIB之抗體 |
| WO2025183966A1 (en) | 2024-02-28 | 2025-09-04 | Versanis Bio, Inc. | Actrii antibodies with extended half life |
| WO2025245160A1 (en) | 2024-05-21 | 2025-11-27 | Scholar Rock, Inc. | Myostatin-selective inhibitors for treating metabolic disorders |
Family Cites Families (125)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| US5013653A (en) | 1987-03-20 | 1991-05-07 | Creative Biomolecules, Inc. | Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| WO1988009344A1 (en) | 1987-05-21 | 1988-12-01 | Creative Biomolecules, Inc. | Targeted multifunctional proteins |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| GB8725529D0 (en) | 1987-10-30 | 1987-12-02 | Delta Biotechnology Ltd | Polypeptides |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| CA2006596C (en) | 1988-12-22 | 2000-09-05 | Rika Ishikawa | Chemically-modified g-csf |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| SE509359C2 (sv) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| JP2938569B2 (ja) | 1990-08-29 | 1999-08-23 | ジェンファーム インターナショナル，インコーポレイティド | 異種免疫グロブリンを作る方法及びトランスジェニックマウス |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
| WO1993011236A1 (en) | 1991-12-02 | 1993-06-10 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| CA2118508A1 (en) | 1992-04-24 | 1993-11-11 | Elizabeth S. Ward | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| ATE427968T1 (de) | 1992-08-21 | 2009-04-15 | Univ Bruxelles | Immunoglobuline ohne leichtkette |
| CA2161351C (en) | 1993-04-26 | 2010-12-21 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
| SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
| US5444047A (en) * | 1994-06-16 | 1995-08-22 | Dipasquale; Gene | Treatment of arthritic and post-surgical orthopedic conditions with Insulin-like Growth Factor-I |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| BR9709006A (pt) | 1996-05-20 | 1999-08-03 | Novo Nordisk As | Processo para obter á partir de sumbstrato protéico um hidrolisado enriquecido com ácido glutámico livre e/ou resíduos de ácido glutámico libados por peptídeo produto alimentício e aditivo de racão animal |
| AU6909298A (en) | 1996-10-28 | 1998-05-22 | Novartis Ag | Method for the oligomerisation of peptides |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| GB2339430A (en) | 1997-05-21 | 2000-01-26 | Biovation Ltd | Method for the production of non-immunogenic proteins |
| US6891082B2 (en) * | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
| US6656475B1 (en) * | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
| AU8666398A (en) | 1997-08-01 | 1999-02-22 | Johns Hopkins University School Of Medicine, The | Methods to identify growth differentiation factor (gdf) receptors |
| US6696260B1 (en) * | 1997-08-01 | 2004-02-24 | The Johns Hopkins University School Of Medicine | Methods to identify growth differentiation factor (GDF) binding proteins |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| PT1071700E (pt) | 1998-04-20 | 2010-04-23 | Glycart Biotechnology Ag | Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| EE05627B1 (et) * | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| ES2694002T3 (es) | 1999-01-15 | 2018-12-17 | Genentech, Inc. | Polipéptido que comprende una región Fc de IgG1 humana variante |
| WO2000061739A1 (fr) | 1999-04-09 | 2000-10-19 | Kyowa Hakko Kogyo Co., Ltd. | Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle |
| DE19932688B4 (de) | 1999-07-13 | 2009-10-08 | Scil Proteins Gmbh | Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen |
| EP1144607B1 (en) | 1999-07-20 | 2008-12-17 | MorphoSys AG | Methods for displaying (poly)peptides/proteins on bacteriophage particles via disulfide bonds |
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| WO2002057445A1 (en) | 2000-05-26 | 2002-07-25 | National Research Council Of Canada | Single-domain brain-targeting antibody fragments derived from llama antibodies |
| ATE309385T1 (de) | 2000-06-28 | 2005-11-15 | Glycofi Inc | Verfahren für die herstellung modifizierter glykoproteine |
| US7060802B1 (en) * | 2000-09-18 | 2006-06-13 | The Trustees Of Columbia University In The City Of New York | Tumor-associated marker |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| KR100857943B1 (ko) | 2000-11-30 | 2008-09-09 | 메다렉스, 인코포레이티드 | 인간 항체의 제조를 위한 형질전환 트랜스염색체 설치류 |
| MA26040A1 (fr) * | 2001-01-05 | 2004-04-01 | Pfizer | Des anticorps pour recepteur i de facteur de croissance insulinique |
| US20050048512A1 (en) | 2001-04-26 | 2005-03-03 | Avidia Research Institute | Combinatorial libraries of monomer domains |
| US20040175756A1 (en) | 2001-04-26 | 2004-09-09 | Avidia Research Institute | Methods for using combinatorial libraries of monomer domains |
| US20050053973A1 (en) | 2001-04-26 | 2005-03-10 | Avidia Research Institute | Novel proteins with targeted binding |
| JP2004532038A (ja) | 2001-05-17 | 2004-10-21 | ディヴァーサ コーポレイション | 新規抗原結合分子の治療、診断、予防、酵素、産業ならびに農業各分野への応用とそのための新規抗原結合分子の作製とスクリーニングの方法 |
| NZ532526A (en) | 2001-10-25 | 2007-01-26 | Genentech Inc | Compositions comprising a glycoprotein having a Fc region |
| WO2003074679A2 (en) | 2002-03-01 | 2003-09-12 | Xencor | Antibody optimization |
| AU2003256336A1 (en) * | 2002-06-28 | 2004-01-19 | Centocor, Inc. | Mammalian epo mimetic ch1 deleted mimetibodies, compositions, methods and uses |
| EP2311867A1 (en) | 2002-10-29 | 2011-04-20 | Anaphore, Inc. | Trimeric binding proteins for trimeric cytokines |
| DE10324447A1 (de) | 2003-05-28 | 2004-12-30 | Scil Proteins Gmbh | Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin |
| KR20060026860A (ko) * | 2003-06-02 | 2006-03-24 | 와이어쓰 | 신경근 장애의 치료를 위한, 코르티코스테로이드와 조합된미오스타틴 (ｇｄｆ８) 저해제의 용도 |
| AU2005207003C1 (en) | 2004-01-20 | 2013-06-13 | Humanigen, Inc. | Antibody specificity transfer using minimal essential binding determinants |
| WO2005116052A2 (en) * | 2004-04-27 | 2005-12-08 | Research Development Foundation | ANTAGONISM OF TGF-β SUPERFAMILY RECEPTOR SIGNALING |
| US20060008844A1 (en) | 2004-06-17 | 2006-01-12 | Avidia Research Institute | c-Met kinase binding proteins |
| EP3059245B1 (en) * | 2004-07-23 | 2018-11-07 | Acceleron Pharma Inc. | Actrii receptor antagonistic antibodies |
| GB0417487D0 (en) * | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| US20060034831A1 (en) * | 2004-08-12 | 2006-02-16 | Wyeth | Combination therapy for diabetes, obesity and cardiovascular diseases using GDF-8 inhibitors |
| CA2538208A1 (en) * | 2005-05-04 | 2006-11-04 | Universite Laval | Modulation of myostatin and use thereof in cell transplantation-based treatment of muscle disease |
| SI1915397T1 (sl) * | 2005-08-19 | 2015-05-29 | Wyeth Llc | Antagonistična protitelesa proti GDF-8 in uporabe pri zdravljenju ALS in drugih obolenj, povezanih z GDF-8 |
| WO2007027957A2 (en) * | 2005-08-31 | 2007-03-08 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in leukemia signaling pathways |
| US8067562B2 (en) * | 2005-11-01 | 2011-11-29 | Amgen Inc. | Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1 |
| MX2008007324A (es) | 2005-12-06 | 2009-03-04 | Amgen Inc | Usos de antagonistas de miostatina. |
| WO2007109668A2 (en) * | 2006-03-20 | 2007-09-27 | The Uab Research Foundation | Compositions and methods for improving bone mass through modulation of novel receptors of pth and fragments thereof |
| WO2007141309A2 (en) | 2006-06-09 | 2007-12-13 | Novartis Ag | Stabilized insulin-like growth factor polypeptides |
| US8097596B2 (en) * | 2006-06-30 | 2012-01-17 | Lakewood-Amedex, Inc. | Compositions and methods for the treatment of muscle wasting |
| EP2054434B1 (en) * | 2006-08-03 | 2017-03-15 | Myostin Therapeutics Pty Ltd | Myostatin antagonists |
| TWI782836B (zh) * | 2007-02-02 | 2022-11-01 | 美商艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
| TWI573802B (zh) | 2007-03-06 | 2017-03-11 | 安美基公司 | 變異之活動素受體多肽及其用途 |
| SG174273A1 (en) * | 2009-04-27 | 2011-10-28 | Novartis Ag | Compositions and methods for increasing muscle growth |
-
2010
- 2010-04-23 SG SG2011064359A patent/SG174273A1/en unknown
- 2010-04-23 SI SI201031603T patent/SI2424895T1/en unknown
- 2010-04-23 KR KR1020117028110A patent/KR101836501B1/ko active Active
- 2010-04-23 BR BRPI1014522A patent/BRPI1014522B8/pt active IP Right Grant
- 2010-04-23 EP EP10714332.3A patent/EP2424895B1/en active Active
- 2010-04-23 PL PL10714332T patent/PL2424895T3/pl unknown
- 2010-04-23 PE PE2011001853A patent/PE20120532A1/es active IP Right Grant
- 2010-04-23 EA EA201650137A patent/EA201650137A1/ru unknown
- 2010-04-23 AU AU2010243697A patent/AU2010243697B2/en active Active
- 2010-04-23 HU HUE10714332A patent/HUE035240T2/hu unknown
- 2010-04-23 EP EP17186736.9A patent/EP3275900A1/en not_active Withdrawn
- 2010-04-23 HR HRP20171870TT patent/HRP20171870T1/hr unknown
- 2010-04-23 MY MYPI2011004217 patent/MY153078A/en unknown
- 2010-04-23 LT LTEP10714332.3T patent/LT2424895T/lt unknown
- 2010-04-23 MA MA34357A patent/MA33279B1/fr unknown
- 2010-04-23 DK DK10714332.3T patent/DK2424895T3/en active
- 2010-04-23 CA CA2993053A patent/CA2993053A1/en not_active Abandoned
- 2010-04-23 NO NO10714332A patent/NO2424895T3/no unknown
- 2010-04-23 NZ NZ595235A patent/NZ595235A/xx unknown
- 2010-04-23 CN CN201510176798.XA patent/CN104725512A/zh active Pending
- 2010-04-23 MX MX2011011352A patent/MX2011011352A/es active IP Right Grant
- 2010-04-23 CN CN201080018660.2A patent/CN102753578B/zh active Active
- 2010-04-23 EA EA201101571A patent/EA027071B1/ru not_active IP Right Cessation
- 2010-04-23 WO PCT/EP2010/055458 patent/WO2010125003A1/en not_active Ceased
- 2010-04-23 AR ARP100101368A patent/AR076402A1/es active IP Right Grant
- 2010-04-23 PT PT107143323T patent/PT2424895T/pt unknown
- 2010-04-23 CA CA2758290A patent/CA2758290C/en active Active
- 2010-04-23 JP JP2012507695A patent/JP5766179B2/ja active Active
- 2010-04-23 ES ES10714332.3T patent/ES2655877T3/es active Active
- 2010-04-23 RS RS20171263A patent/RS56661B1/sr unknown
- 2010-04-25 JO JOP/2010/0127A patent/JO3313B1/ar active
- 2010-04-26 TW TW099113107A patent/TWI528974B/zh active
- 2010-04-26 US US12/767,509 patent/US8388968B2/en active Active
- 2010-04-26 TW TW104130328A patent/TW201615213A/zh unknown
- 2010-04-27 UY UY0001032583A patent/UY32583A/es active IP Right Grant
-
2011
- 2011-09-07 ZA ZA2011/06538A patent/ZA201106538B/en unknown
- 2011-09-12 TN TN2011000463A patent/TN2011000463A1/fr unknown
- 2011-09-15 IL IL215168A patent/IL215168A0/en active IP Right Grant
- 2011-09-16 CR CR20110487A patent/CR20110487A/es unknown
- 2011-10-26 HN HN2011002817A patent/HN2011002817A/es unknown
- 2011-10-26 CL CL2011002660A patent/CL2011002660A1/es unknown
- 2011-10-26 SV SV2011004043A patent/SV2011004043A/es unknown
- 2011-10-27 CU CU2011000199A patent/CU23945B1/es unknown
- 2011-11-11 CO CO11154165A patent/CO6460759A2/es active IP Right Grant
- 2011-11-25 EC EC2011011484A patent/ECSP11011484A/es unknown
-
2012
- 2012-05-31 US US13/485,399 patent/US8551482B2/en active Active
-
2013
- 2013-08-29 US US14/013,707 patent/US20130344091A1/en not_active Abandoned
-
2014
- 2014-03-28 JP JP2014070238A patent/JP2014158480A/ja not_active Withdrawn
-
2015
- 2015-07-23 US US14/806,997 patent/US20180134791A9/en not_active Abandoned
-
2016
- 2016-06-30 JP JP2016129498A patent/JP2017014207A/ja active Pending
-
2017
- 2017-12-06 CY CY20171101282T patent/CY1119664T1/el unknown
-
2018
- 2018-02-27 US US15/906,703 patent/US20180194846A1/en not_active Abandoned
-
2024
- 2024-01-26 US US18/424,004 patent/US20240425602A1/en active Pending